Pre–CAR-T B-cell–directed immunotherapy exposure and outcomes after CD19 CAR-T for large B-cell lymphoma: An EBMT registry analysis
Jan C. Schroeder, Christophe Peczynski, Philipp Berning, Eva Michel et autres
0 citationsBone Marrow Transplantation
Christophe Peczynski
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
76Publications signalées
880Citations signalées
2Affiliations récentes
Institutions déclarées
Domaines associés
Hematopoietic Stem Cell TransplantationAcute Lymphoblastic Leukemia researchCAR-T cell therapy researchRenal Transplantation Outcomes and TreatmentsAcute Myeloid Leukemia Research
Publications récentes
Does size matter? Impact Of Body Mass Index On Outcome Of Anti-CD19 CAR-T Cell Therapy For B-Cell Lymphoma
Christian Schultze‐Florey, Christophe Peczynski, William Boreland, Marc Wehrli et autres
0 citationsBlood Immunology & Cellular Therapy
Thrombotic microangiopathy following CAR T-cell therapy: a case series from the EBMT Complications Working Party
Guillaume Dachy, William Boreland, Eugenio Galli, Emmanuel Gyan et autres
0 citationsHaematologica
Complications of Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide—A Prospective Study on Behalf of the EBMT Transplant Complications Working Party
Agnieszka Tomaszewska, Grzegorz Basak, Christophe Peczynski, Emmanuelle Polge et autres
2 citationsCancers
Complications of Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide—A Prospective Study on Behalf of the EBMT Transplant Complications Working Party
Agnieszka Tomaszewska, Grzegorz W. Basak, Christophe Peczynski, Emmanuelle Polge et autres
0 citationsDipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
Impact of prior B-cell-directed immunotherapy on the outcome of CD19 CAR T-cell therapy in aggressive B-cell lymphoma - an analysis of the EBMT and the GoCART coalition
Jan C. Schroeder, Christophe Peczynski, Philipp Berning, Eva Michel et autres
0 citationsBlood
Improved GVHD-free relapse-free survival when rATG/ATLG is used in allo-HCT from matched sibling donors - an EBMT registry study by the Transplant Complications Working Party
Agnieszka Piekarska, Mouad Abouqateb, William Boreland, Christophe Peczynski et autres
3 citationsBone Marrow Transplantation
Post-transplantation cyclophosphamide and antithymocyte globulin in 8/10 HLA-mismatched unrelated donor transplantation: the analysis on behalf of the transplant complications working party of the EBMT
Ivan Moiseev, Mouad Abouqateb, Christophe Peczynski, Alessandro Busca et autres
1 citationBone Marrow Transplantation
Chronic Graft-versus-Host disease trends over 30 years - a study by the EBMT transplant complications working party
Dražen Pulanić, Christophe Peczynski, William Boreland, Christina Rautenberg et autres
4 citationsBone Marrow Transplantation
Graft‐versus‐host disease is not associated with reduced incidence of relapse following haploidentical stem cell transplantation with post‐transplant cyclophosphamide for acute lymphoblastic leukaemia: A study on behalf of the Acute Leukaemia Working Party of European Society for Blood and Marrow Transplantation
Avichai Shimoni, Christophe Peczynski, Myriam Labopin, Alida Dominietto et autres
3 citationsBritish Journal of Haematology
Daratumumab for PRCA after HCT: study and practical considerations from the EBMT Transplant Complications Working Party
Nico Gagelmann, Moniek de Witte, Christophe Peczynski, William Boreland et autres
6 citationsBlood Cancer Journal
GVHD prophylaxis in matched related stem cell transplantation: Why post-transplant cyclophosphamide can be recommended a study by the EBMT transplant complications working party
O. Penack, Mouad Abouqateb, Christophe Peczynski, William Boreland et autres
0 citationsZurich Open Repository and Archive (University of Zurich)
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.